Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifarizine SCHEMBL8963776 | 0.99 | DRD2 (0.56) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL9424741 | 0.95 | DRD3 (0.55) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8964084 | 0.94 | DRD2 (0.52) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963668 | 0.94 | DRD2 (0.64) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963644 | 0.92 | DRD3 (0.56) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| Lifarizine SCHEMBL9494261 | 0.92 | CYP3A4 (0.50) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963661 | 0.90 | CYP3A4 (0.49) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963806 | 0.90 | CYP3A4 (0.56) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963501 | 0.90 | CTSS (0.52) | DRD2DRD4DRD3CYP3A4CYP2C19 | |
| SCHEMBL8963465 | 0.89 | LMNA (0.57) | DRD2DRD4DRD3CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5514800-A | CALCIUM CHANNEL BLOCKERS, CEREBRAL ISCHEMIA | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1996-05-07 | — | — | US | claimed |
| US-5276034-A | Cardiovascular disorders, nervous system disorders, diuretics, antiischemic agents or antispasmodic agents | SYNTEX PHARMACEUTICAL LTD. (GB) | 1994-01-04 | — | — | US | claimed |
| EP-0365363-B1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1993-04-14 | — | — | EP | claimed |
| EP-0289227-B1 | SUBSTITUTED IMIDAZOLYL-ALKYL-PIPERAZINE AND -DIAZEPINE DERIVATIVES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1992-04-08 | — | — | EP | claimed |
| US-5063220-A | Strokes | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1991-11-05 | — | — | US | claimed |
| US-5043447-A | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1991-08-27 | — | — | US | claimed |
| US-4973591-A | SALT FORMATION IN SITU, TREATMENT OF STROKES | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1990-11-27 | — | — | US | claimed |
| EP-0365363-A1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1990-04-25 | — | — | EP | claimed |
| US-4829065-A | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1989-05-09 | — | — | US | claimed |
| EP-0289227-A1 | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS LTD. (GB) | 1988-11-02 | — | — | EP | claimed |
| JP-2157224-A | — | — | None | — | — | JP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20250352653-A1 | NEURON TARGETED 2-DEOXYGLUCOSE DENDRIMER FOR IMAGING AND TREATMENT OF NEUROLOGICAL DISEASES | UNIV WASHINGTON STATE (US) | 2025-11-20 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| CN-116710090-A | Heteroaryl amide inhibitors of CD38 | NAPA医疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-0365363-A1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1990-04-25 | — | — | EP | disclosed |
| EP-0365363-A1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1990-04-25 | — | — | EP | disclosed |
| EP-0365363-A1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1990-04-25 | — | — | EP | disclosed |
| US-4829065-A | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1989-05-09 | — | — | US | disclosed |
| EP-0289227-A1 | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS LTD. (GB) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | DRD2 3006/4885DRD4 3683/4885DRD3 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.